Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase EARLY_PHASE1 1Phase 2/3 1Phase 1/2 1Phase 1 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Hemangioma, Capillary 2Ulcer 1Recurrent respiratory papillomatosis 1Papilloma 1Melanoma 1

Interventions

Nivolumab 7Ipilimumab 4pembrolizumab 3Interferon alpha-2 3relatlimab 2Drug Therapy 2Dacarbazine 2sargramostim 1salicylhydroxamic acid 1peginterferon alfa-2b 1peginterferon alfa-2a 1molgramostim 1entrectinib 1cyclopropapyrroloindole 1cobimetinib 1atezolizumab 1Vemurafenib 1Triamcinolone Acetonide 1Temozolomide 1Specimen Handling 1Sonazoid 1Ranibizumab 1Propranolol 1Lenalidomide 1Introns 1Immunotherapy 1Imiquimod 1Fatty Acids, Omega-3 1Crizotinib 1Colony-Stimulating Factors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Melanoma × Propranolol × Clear all
NCT02962947 2016-11-15

MELABLOCK: A Clinical Trial on the Efficacy and Safety of Propranolol 80 mg in Melanoma Patients

Azienda Sanitaria di Firenze

Phase 2/3 Unknown
546 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡